Abstract
LITHIUM is an effective therapeutic agent in the treatment and prevention of the manic phase of manic-depression1, and although known to influence many physiological systems, no specific mechanism has been identified for its efficacy in this illness2. One postulated primary site of Li action is as an inhibitor of hormone-stimulated adenylate cyclase3. Li inhibits the ADH-sensitive adenylate cyclase in kidney4,5, the TSH-sensitive adenylate cyclase in thyroid6,7, the prostaglandin-sensitive adenylate cyclase in human platelets8,9, and the noradrenaline-sensitive adenylate cyclase in rat brain10,11.
| Original language | English |
|---|---|
| Pages (from-to) | 411-413 |
| Number of pages | 3 |
| Journal | Nature |
| Volume | 259 |
| Issue number | 5542 |
| DOIs | |
| State | Published - 1976 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver